Biomarker-targeted Trial to Optimize Treatment for Patients With Chronic Kidney Disease
Chronic Kidney Disease
Enrolment: 125 · Results not recorded
Loading the evidence…
Drug · Mineralocorticoid receptor antagonist (ANTAGONIST, direct interaction, disease efficacy true; ChEMBL mec_id 4578). ATC C03DA05.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Chronic Kidney Disease
Enrolment: 125 · Results not recorded
Chronic Kidney Disease · Type 2 Diabetes Mellitus
Enrolment: 200 · Results not recorded
Type 2 Diabetes Mellitus · Chronic Kidney Disease · Cardiovascular Diseases
Enrolment: 80 · Results not recorded
Type 2 Diabetes
Enrolment: 82 · Results not recorded
IgA Nephropathy
Enrolment: 120 · Results not recorded
Hypertension
Enrolment: 30 · Results not recorded
Type 2 Diabetes
Enrolment: 91 · Results not recorded
Left Ventricular Systolic Dysfunction · Heart Failure
Enrolment: 117 · Results not recorded
Renal Cell Carcinoma · Chronic Kidney Disease
Enrolment: 10 · Results not recorded
Diabetic Retinopathy
Enrolment: 70 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Electric denudation injury of the left common carotid artery (2 W for 2 seconds per millimetre over 4 mm) and wire-induced dilation injury of the femoral artery (0.38 mm straight spring wire advanced 1 cm and left in place for 1 minute)
Finerenone at 10 nM prevented aldosterone-induced smooth muscle cell proliferation and at 1 nM prevented endothelial cell apoptosis in vitro. In vivo, re-endothelialisation at day 3 increased from 0.52 plus or minus 0.12 mm with vehicle to 1.13 plus or minus 0.16 mm at 1 mg/kg/day and 1.083 plus or…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.